Antifungal Susceptibility Tests and the cyp51 Mutant Strains among Clinical Aspergillus fumigatus Isolates from Korean Multicenters

References

• Patterson TF, Thompson GR, 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–e60.
   PubMed Web of Science ®Google Scholar
• Rivero-Menendez O, Alastruey-Izquierdo A, Mellado E, et al. Triazole resistance in Aspergillus spp.: a worldwide problem? J Fungi. 2016;2(3):21.
   Web of Science ®Google Scholar
• Verweij PE, Snelders E, Kema GH, et al. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?. Lancet Infect Dis. 2009;9(12):789–795.
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Gil VG, Gutierrez F, et al. First detection of TR34 L98H and TR46 Y121F T289A Cyp51 mutations in Aspergillus fumigatus isolates in the United States. J Clin Microbiol. 2016;54(1):168–171.
   PubMed Web of Science ®Google Scholar
• Escribano P, Recio S, Peláez T, et al. Aspergillus fumigatus strains with mutations in the cyp51A gene do not always show phenotypic resistance to itraconazole, voriconazole, or posaconazole. Antimicrob Agents Chemother. 2011;55(5):2460–2462.
   PubMed Web of Science ®Google Scholar
• Kidd SE, Goeman E, Meis JF, et al. Multi-triazole-resistant Aspergillus fumigatus infections in Australia. Mycoses. 2015;58(6):350–355.
   PubMed Web of Science ®Google Scholar
• Pham CD, Reiss E, Hagen F, et al. Passive surveillance for azole-resistant Aspergillus fumigatus, United States, 2011–2013. Emerg Infect Dis. 2014;20(9):1498–1503.
   PubMed Web of Science ®Google Scholar
• Chen Y, Lu Z, Zhao J, et al. Epidemiology and molecular characterizations of azole resistance in clinical and environmental Aspergillus fumigatus isolates from China. Antimicrob Agents Chemother. 2016;60(10):5878–5884.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Cho SY, Lee DG, et al. TR34/L98H Mutation in CYP51A Gene in Aspergillus fumigatus clinical isolates during posaconazole prophylaxis: first case in Korea. Mycopathologia. 2018;183(4):731–736.
   Web of Science ®Google Scholar
• Heo MS, Shin JH, Choi MJ, et al. Molecular identification and amphotericin B susceptibility testing of clinical isolates of Aspergillus from 11 hospitals in Korea. Ann Lab Med. 2015;35(6):602–610.
   PubMed Web of Science ®Google Scholar
• CLSI. 2008. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. 2nd ed. CLSI document M38-A2. Wayne, PA: Clinical and Laboratory Standards Institute.
   Google Scholar
• Espinel-Ingroff A, Turnidge J. The role of epidemiological cutoff values (ECVs/ECOFFs) in antifungal susceptibility testing and interpretation for uncommon yeasts and moulds. Rev Iberoam Micol. 2016;33(2):63–75.
   Web of Science ®Google Scholar
• Garcia-Rubio R, Alcazar-Fuoli L, Monteiro MC, et al. Insight into the significance of Aspergillus fumigatus cyp51A polymorphisms. Antimicrob Agents Chemother. 2018;62(6):e00241–18.
   PubMed Web of Science ®Google Scholar
• van der Linden J, Arendrup M, Warris A, et al. Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. Emerg Infect Dis. 2015;21(6):1041–1044.
   PubMed Web of Science ®Google Scholar
• Fraczek MG, Bromley M, Buied A, et al. The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother. 2013;68(7):1486–1496.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E, et al. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigates. Antimicrob Agents Chemother. 2008;52(7):2468–2472.
   PubMed Web of Science ®Google Scholar
• Snelders E, Karawajczyk A, Schaftenaar G, et al. Azole resistance profile of amino acid changes in Aspergillus fumigatus CYP51A based on protein homology modeling. Antimicrob Agents Chemother. 2010;54(6):2425–2430.
   PubMed Web of Science ®Google Scholar
• Snelders E, Huis In ‘T Veld RA, Rijs AJ, et al. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol. 2009;75(12):4053–4057.
   PubMed Web of Science ®Google Scholar
• Diaz-Guerra TM, Mellado E, Cuenca-Estrella MA, et al. A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother. 2003;47(3):1120–1124.
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–1821.
   PubMed Web of Science ®Google Scholar